Abstract |
The echinocandins are a new class of antifungal that have shown promising results in treating a variety of fungal infections. Anidulafungin is the newest approved echinocandin and may have some advantages over existing antifungals. It has activity against a broad range of fungi. It is unique because it undergoes a process of slow chemical degradation rather than being metabolised. Studies evaluating the use of anidulafungin in combination with other commonly used drugs have not demonstrated any significant drug-drug interactions or adverse events. Thus far, anidulafungin appears to have an excellent safety profile with few adverse events. Based on early clinical experience, it appears that anidulafungin will be a valuable and safe asset in the management of serious and difficult-to-treat fungal infections.
|
Authors | José A Vazquez |
Journal | Expert opinion on drug safety
(Expert Opin Drug Saf)
Vol. 5
Issue 6
Pg. 751-8
(Nov 2006)
ISSN: 1744-764X [Electronic] England |
PMID | 17044802
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antifungal Agents
- Echinocandins
- Peptides, Cyclic
- Anidulafungin
|
Topics |
- Anidulafungin
- Animals
- Antifungal Agents
(adverse effects, blood)
- Echinocandins
- Humans
- Peptides, Cyclic
(adverse effects, blood)
|